Prognostic and predictive biomarkers in colorectal cancer: from established molecular markers to Mediator complex-related transcriptional reprogramming-a narrative review.
- 1Department of Gastrointestinal Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Abstract
Colorectal cancer (CRC) prognosis and treatment selection are increasingly informed by established molecular biomarkers, circulating tumor DNA (ctDNA), immune contexture, and multidimensional prediction models. However, these approaches mainly define tumor identity, treatment eligibility, residual disease burden, or observable tumor states and may incompletely explain how adaptive transcriptional states arise under oncogenic, stromal, immune, metastatic, or therapeutic pressure. This review evaluates Mediator complex-related transcriptional programs as a candidate regulatory layer that may complement existing CRC biomarker frameworks. English-language literature was reviewed using PubMed/MEDLINE, Web of Science, and Scopus, with Google Scholar used for citation tracking. The initial search was performed on June 7, 2026, and a focused supplementary update was performed on August 17, 2026. Recent CRC biomarker studies, Mediator-related transcriptional regulation, functional heterogeneity, therapy adaptation, and germline variation in Mediator-related genes were emphasized, while earlier landmark mechanistic studies and guidelines were retained when necessary. Established clinicopathological and molecular biomarkers primarily define baseline risk, molecular identity, and treatment eligibility. Dynamic and multidimensional approaches add residual-disease, immune, stromal, spatial, and transcriptomic state information. Mediator-related programs may provide a mechanistic interpretation layer by linking transcription-factor and enhancer inputs, chromatin context, and RNA polymerase II-dependent output. Cyclin-dependent kinase 8 (CDK8)-Wnt/β-catenin represents a mechanistically strong CRC axis; Mediator subunit 12 (MED12)-linked transforming growth factor-β (TGF-β)/epithelial-mesenchymal transition (EMT) programs are strongly context dependent; emerging cyclin-dependent kinase 19 (CDK19) evidence links metabolic remodeling with immune-evasive states; and Mediator subunits 19 and 28 remain lower-maturity candidates. Current evidence does not establish germline MED12/CDK8 variants as CRC prognostic or predictive biomarkers. CRC biomarker development should integrate rather than replace complementary information layers. Mediator-related programs are not mature stand-alone clinical biomarkers but may help interpret adaptive tumor states. Prospective clinically annotated cohorts, functional perturbation, single-cell and spatial profiling, and demonstration of incremental value beyond established biomarkers are required before clinical implementation.
Related
- Immune and Circulating Biomarkers in Hepatocellular Carcinoma: Prognostic and Predictive Relevance for Immunotherapy
- Circulating leucine-rich α-2 glycoprotein 1 and its prognostic significance in established heart failure
- Comparison of Established and Emerging Biomarkers Across Estimated GFR
- Stepwise bladder carcinogenesis reveals transcriptional reprogramming involving MMP1 and COL7A1
- A Novel ACLY Inhibitor Induces Transcriptional and Metabolic Reprogramming to Overcome Tyrosine kinase inhibitor Resistance in Lymphoma
BibTeX
@article{han2026prognostic,
title = {{Prognostic and predictive biomarkers in colorectal cancer: from established molecular markers to Mediator complex-related transcriptional reprogramming-a narrative review.}},
author = {Mengqian Han and Yijia Mao and Haidong Cheng},
journal = {Journal of gastrointestinal oncology},
year = {2026},
month = sep,
doi = {10.21037/jgo-2026-0686},
url = {https://europepmc.org/article/MED/42996867},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Prognostic and predictive biomarkers in colorectal cancer: from established molecular markers to Mediator complex-related transcriptional reprogramming-a narrative review.
AU - Mengqian Han
AU - Yijia Mao
AU - Haidong Cheng
PY - 2026
DA - 2026/09/28
JO - Journal of gastrointestinal oncology
DO - 10.21037/jgo-2026-0686
UR - https://europepmc.org/article/MED/42996867
AB - Colorectal cancer (CRC) prognosis and treatment selection are increasingly informed by established molecular biomarkers, circulating tumor DNA (ctDNA), immune contexture, and multidimensional prediction models. However, these approaches mainly define tumor identity, treatment eligibility, residual disease burden, or observable tumor states and may incompletely explain how adaptive transcriptional states arise under oncogenic, stromal, immune, metastatic, or therapeutic pressure. This review evaluates Mediator complex-related transcriptional programs as a candidate regulatory layer that may complement existing CRC biomarker frameworks. English-language literature was reviewed using PubMed/MEDLINE, Web of Science, and Scopus, with Google Scholar used for citation tracking. The initial search was performed on June 7, 2026, and a focused supplementary update was performed on August 17, 2026. Recent CRC biomarker studies, Mediator-related transcriptional regulation, functional heterogeneity, therapy adaptation, and germline variation in Mediator-related genes were emphasized, while earlier landmark mechanistic studies and guidelines were retained when necessary. Established clinicopathological and molecular biomarkers primarily define baseline risk, molecular identity, and treatment eligibility. Dynamic and multidimensional approaches add residual-disease, immune, stromal, spatial, and transcriptomic state information. Mediator-related programs may provide a mechanistic interpretation layer by linking transcription-factor and enhancer inputs, chromatin context, and RNA polymerase II-dependent output. Cyclin-dependent kinase 8 (CDK8)-Wnt/β-catenin represents a mechanistically strong CRC axis; Mediator subunit 12 (MED12)-linked transforming growth factor-β (TGF-β)/epithelial-mesenchymal transition (EMT) programs are strongly context dependent; emerging cyclin-dependent kinase 19 (CDK19) evidence links metabolic remodeling with immune-evasive states; and Mediator subunits 19 and 28 remain lower-maturity candidates. Current evidence does not establish germline MED12/CDK8 variants as CRC prognostic or predictive biomarkers. CRC biomarker development should integrate rather than replace complementary information layers. Mediator-related programs are not mature stand-alone clinical biomarkers but may help interpret adaptive tumor states. Prospective clinically annotated cohorts, functional perturbation, single-cell and spatial profiling, and demonstration of incremental value beyond established biomarkers are required before clinical implementation.
SN - 2078-6891
SN - 2219-679X
ER -